Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis in the real-world setting: Interim results from the Plegridy Observational Program
Marco Salvetti, Sibyl Wray, Gereon Nelles, Arman Altincatal, Achint Kumar, Thijs Koster, Maria L. Naylor
Topics & Concepts
MedicineDiscontinuationInternal medicineIncidence (geometry)Confidence intervalObservational studyAdverse effectPopulationInterim analysisMultiple sclerosisRate ratioPediatricsClinical trialImmunologyPhysicsEnvironmental healthOpticsMultiple Sclerosis Research StudiesPeripheral Neuropathies and DisordersSystemic Sclerosis and Related Diseases